Now that Pfizer (NYSE:PFE)'s Upjohn and Mylan (NASDAQ:MYL) are combining in a new spinoff, it looks like Teva (NYSE:TEVA) could be next. Judging by price movements in Teva since Pfizer made its move, some traders may be anticipating this. The stock is up nearly 7% since the deal was announced.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,